A single center retrospective study on surgical efficacy of T3NxM0 middle-low rectal cancer without neoadjuvant therapy.
- Author:
Peng LIU
1
;
Zheng LOU
1
;
Zubing MEI
2
;
Xianhua GAO
1
;
Liqiang HAO
1
;
Lianjie LIU
1
;
Haifeng GONG
1
;
Ronggui MENG
1
;
Enda YU
1
;
Hantao WANG
1
;
Hao WANG
1
;
Wei ZHANG
3
Author Information
1. Department of Colorectal Surgery, Changhai Hospital, Navy Military Medical University, Shanghai 200082, China.
2. Department of Colorectal Disease, Shuguang Hospital, Shanghai Traditional Chinese Medicine University, Shanghai 201203, China.
3. Department of Colorectal Surgery, Changhai Hospital, Navy Military Medical University, Shanghai 200082, China. Email: weizhang2000cn@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Lymph Node Excision;
Lymph Nodes;
pathology;
surgery;
Lymphatic Metastasis;
Mesocolon;
surgery;
Neoadjuvant Therapy;
Neoplasm Staging;
Proctectomy;
methods;
Prognosis;
Rectal Neoplasms;
pathology;
surgery;
Retrospective Studies
- From:
Chinese Journal of Gastrointestinal Surgery
2019;22(1):66-72
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the surgical efficacy and prognostic factors of T3NxM0 middle-low rectal cancer without neoadjuvant therapy.
METHODS:Clinical data of patients with middle-low rectal cancer undergoing TME surgery with T3NxM0 confirmed by postoperative pathology at Colorectal Surgery Department of Changhai Hospital from January 2008 to December 2010 were analyzed retrospectively.
INCLUSION CRITERIA:(1)no preoperative neoadjuvant chemoradiotherapy (nCRT); (2) complete preoperative evaluation, including medical history, preoperative colonoscopy or digital examination, blood tumor marker examination, and imaging examination; (3) distance between tumor lower margin and anal verge was ≤ 10 cm; (4) negative circumferential resection margin (CRM-). Finally, a total of 331 patients were included in this study. According to the number of metastatic lymph node confirmed by postoperative pathology, the patients were divided into N0 group without regional lymph node metastasis (190 cases) and N+ group with regional lymph node metastasis (141 cases). The perioperative conditions, local recurrence, distant metastasis and prognostic factors were analyzed.
RESULTS:Compared to N0 group in the perioperative data, N+ group had higher ratio of tumor deposit [29.8%(42/141) vs. 0, χ²=64.821, P<0.001] and vascular invasion [7.1%(10/141) vs. 0.5%(1/190),χ²=10.860, P<0.001]. There were no significant differences in tumor diameter, number of lymph nodes detected, positive nerve invasion, degree of tumor differentiation, morbidity of postoperative complication and postoperative adjuvant chemotherapy rate between the two groups (all P>0.05). The median follow-up period was 73.4 months. The merged 5-year local recurrence rate was 2.7%(9/331), 5-year distant metastasis rate was 23.3% (77/331), 5-year disease-free survival (DFS) rate was 73.4%, and 5-year overall survival (OS) rate was 77.2%. Multivariate analysis showed that lymph node metastasis (HR=3.120, 95%CI: 1.918 to 5.075, P<0.001), nerve invasion (HR=0.345, 95%CI: 0.156 to 0.760, P=0.008) and vascular invasion (HR=0.428, 95%CI: 0.189 to 0.972, P=0.043) were independent risk factors for DFS in patients with T3NxM0 rectal cancer after operation. Preoperative carcinoembryonic antigen level (HR=1.858, 95%CI:1.121 to 3.079, P=0.016), lymph node metastasis (HR=3.320, 95%CI: 1.985 to 5.553, P<0.001) and nerve invasion (HR=0.339, 95%CI: 0.156 to 0.738, P=0.006) were independent risk factors for OS in patients with T3NxM0 rectal cancer after operation.
CONCLUSIONS:Optimal local control rate of middle-low rectal cancer patients with T3NxM0 and CRM- can be achieved by standard TME surgery alone. For patients with preoperative elevated blood carcinoembryonic antigen level, regional lymph node metastasis, or neurovascular invasion confirmed by pathology after surgery, adjuvant chemoradiotherapy should be actively applied after surgery to improve prognosis.
